Related Experiment Video
Updated: Nov 5, 2025
06:21
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
939
Genetic Polymorphisms and Pharmacotherapy for Prostate Cancer
Masaki Shiota1, Shusuke Akamatsu2, Shintaro Narita3
1Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
JMA Journal
|May 17, 2021
Summary
Genetic variations like single-nucleotide polymorphisms (SNPs) can predict prostate cancer treatment success. Identifying these genetic biomarkers enables personalized medicine for better pharmacotherapy outcomes.
Area of Science:
- Oncology
- Pharmacogenomics
- Cancer Biomarkers
Background:
- The treatment of prostate cancer has expanded, necessitating biomarkers for personalized pharmacotherapy.
- Genetic factors, including polymorphisms, influence patient response to cancer drugs.
- Identifying genetic markers is crucial for optimizing prostate cancer treatment strategies.
Purpose of the Study:
- To review the impact of genetic polymorphisms on prostate cancer pharmacotherapy outcomes.
- To highlight the potential of genetic variations as predictive biomarkers.
- To discuss current challenges and future directions in the field.
Main Methods:
- Literature review of studies investigating genetic polymorphisms in prostate cancer patients.
- Analysis of associations between genetic variations (SNPs, tandem repeats) and treatment response.
- Examination of polymorphisms in genes related to androgen receptor signaling, drug metabolism, and efflux pumps.
Main Results:
- Genetic polymorphisms in androgen receptor signaling pathways correlate with outcomes of androgen-deprivation therapy and receptor-pathway inhibitors.
- SNPs in drug metabolism and efflux pump genes are linked to the efficacy of taxane chemotherapy.
- Genetic variations serve as promising biomarkers for personalized prostate cancer medicine.
Conclusions:
- Genetic polymorphisms, particularly SNPs, are valuable biomarkers for tailoring prostate cancer pharmacotherapy.
- Personalized medicine approaches utilizing genetic information can enhance treatment efficacy.
- Further research is needed to fully integrate genetic profiling into clinical practice for prostate cancer.
More Related Videos
Related Concept Videos
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
53
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
53
02:50Combination Therapies and Personalized Medicine
5.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K
01:27Nonlinear Pharmacokinetics: Role of Transporters
134
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
134
01:24Dosage Regimen: Individualization
42
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
42
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
46
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
46
01:05Single Nucleotide Polymorphisms-SNPs
17.2K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.2K